ASO therapy rescues NOTCH2NLC GGC repeat expansion-induced genomic damage, 3D chromatin structural abnormalities, and senescence.
Lab-grown brain tissue proves antisense therapy can reverse the cellular damage from a rare inherited neurological disease, opening a treatment path forward.
This Nature Communications study demonstrates that antisense oligonucleotide therapy can rescue the genomic damage and cellular senescence caused by NOTCH2NLC repeat expansion in neuronal intranuclear inclusion disease. Using patient-derived brain organoids, the researchers provide proof-of-concept for a targeted therapeutic approach to this rare neurodegenerative condition.
What the study was
- Study design
- Preclinical mechanistic study with brain organoids
- Population
- NIID patient-derived brain organoids
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Nature communications
Why it surfaced
First proof-of-concept ASO therapy for NIID in Nature Comms. Preclinical but addresses rare disease with zero approved treatments.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.